Orexigen shares hit by FDA delay in obesity drug By: CNBC.com News June 11, 2014 at 10:07 AM EDT Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements. Read More >> Related Stocks: Vivus Inc